

RECEIVED

9P1646

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
MAY 21 2001
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
MAY 24, 2001
CONN001/Conf. #6620

In Re Application of
CONRAD ET AL.

TECH CENTER 1600/2900

Conrad et al.

11/3
DB
5/25/01

Serial No.
09/780,752

Filing Date
February 9, 2001

Examiner
Unassigned

Group Art Unit
1646

Title:

Use of Relaxin Treat Diseases Related to Vasoconstriction.

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

a certification as specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))


RECEIVED

Docket No.

COM 012 Cinf #6620

In Re Application Of:
Conrad et al.

TECH CENTER 1600/2900



Serial No.
09/780,752

Filing Date
February 9, 2001

Examiner
Unassigned

Group Art Unit
1646

Title:

Use of Relaxin Treat Diseases Related to Vasoconstriction.

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0815 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Paula A. Borden
Reg. No. 42,344
Bozicevic, Field & Francis, LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
(650) 327-3400

Return Receipt Postcard

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 5/17/01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Barbara M. Weatherly

Typed or Printed Name of Person Mailing Correspondence

Dated: May 16, 2001

CC:

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) Use several sheets if necessary			ATTY. DOCKET NO. CONN001	RECEIVED 09/780,752
			APPLICANT	MAY 24 2001
			FILING DATE February 9, 2001	GROUP Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
swl	AA	4,624,804	11/25/1986	Voelter et al.	—	—	
swl	AB	5,166,191	11/24/1992	Cronin et al.	—	—	
swl	AC	5,952,296	09/14/1999	Bigazzi	—	—	


FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
swl	AD	WO 95/07711	03/23/1995	PCT	—	—	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

swl	AE	Charney et al. (1993) "The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size." <i>Am. Heart J.</i> , Vol. 126:937-945.
swl	AF	Harada et al. (1994) "Basic Fibroblast Growth Factor Improves Myocardial Function in Chronically Ischemic Porcine Hearts." <i>J. Clin. Invest.</i> , Vol. 94:623-630.
swl	AG	Henry (1999) "Therapeutic Angiogenesis" <i>BMJ</i> , Vol. 318:1536-9.
swl	AH	Lopez et al. (1998) "VEGF administration in chronic myocardial ischemia in pigs." <i>Cardiovascular Research</i> , Vol. 40:272-281.
swl	AI	Losordo et al. (1998) "Gene Therapy for Myocardial Angiogenesis." <i>Circulation</i> , Vol. 98:2800-2804.
swl	AJ	Patel et al. (1999) "Safety of Direct Myocardial Administration of an Adenovirus Vector Encoding Vascular Endothelial Growth Factor 121." <i>Human Gene Therapy</i> , Vol. 10:1331-1348.
swl	AK	Unger et al. (1994) "Basic fibroblast growth factor enhances myocardial collateral flow in a canine model." <i>Am. J. Physiol.</i> , Vol. 266:H1588-1595.
swl	AL	Yang et al. (1998) "Substantially Attenuated Hemodynamic Responses to Escherichia coli-Derived Vascular Endothelial Growth Factor Given by Intravenous Infusion Compared with Bolus Injection." <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 284(1):103-110.

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER		DATE CONSIDERED	11-18-2002
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			